종양용해성 바이러스 요법 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 바이러스 유형별, 용도별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Virus Type, By Application, by End User, By Region & Competition, 2020-2030F
세계 종양용해성 바이러스 요법 시장은 2024년 165억 7,000만 달러로 평가되었고, 예측 기간 동안 22.92%의 연평균 복합 성장률(CAGR)로 2030년에는 571억 5,000만 달러에 달할 것으로 예상됩니다.
종양용해성 바이러스는 암세포에 감염되어 선택적으로 복제하여 암세포를 파괴하거나 프로그램된 세포사멸(apoptosis)을 유발할 수 있는 바이러스의 일종입니다. 이러한 바이러스는 종양 선택적 선호성을 보이도록 조작된 것이거나 자연적으로 발생한 것입니다. 즉, 정상세포와 건강한 세포는 피해가고 암세포를 표적으로 삼아 복제하는 선천적인 능력을 가지고 있습니다. 종양용해성 바이러스는 표적화된 혁신적인 치료법으로서의 가능성으로 암 치료 분야에서 주목받으며 중요하게 여겨지고 있습니다. 암세포 용해성 바이러스는 암세포 내에 감염되어 복제하는 것을 선호하는 성질을 가지고 있습니다. 이 선택성은 대부분 암세포와 정상세포의 세포 인자 및 분자적 특성의 차이에 기반합니다. 암세포 내에 들어가면 온콜레티큘러 바이러스는 복제 및 증식합니다. 이 복제는 결국 암세포의 용해(파열)로 이어지고, 새로 형성된 바이러스 입자를 방출하여 인접한 암세포를 감염시킵니다. 이 과정은 계속되어 종양 전체에 효과적으로 감염을 퍼뜨립니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
165억 7,000만 달러 |
| 시장 규모 : 2030년 |
571억 5,000만 달러 |
| CAGR : 2025-2030년 |
22.92% |
| 급성장 부문 |
단순 헤르페스 바이러스(HSV) |
| 최대 시장 |
북미 |
지속적인 연구 개발로 온콜레스테롤 바이러스에 대한 이해가 깊어지고, 보다 강력하고 표적화된 치료법을 개발할 수 있게 되었습니다. 이러한 과학적 진보는 이 분야의 기술 혁신을 촉진하고 있습니다. 다양한 암종에 대한 종양컬 바이러스 치료의 임상시험과 실제 임상 적용에서 좋은 결과가 나오면서 그 효과에 대한 신뢰가 높아지고 있습니다. 환자의 생존 이익과 결과 개선을 입증하는 것이 중요한 원동력이 되고 있습니다. 온콜로바이러스 요법을 면역요법이나 표적치료제와 같은 다른 치료법과 병용하는 개념이 지지받고 있습니다. 이러한 병용요법은 암 치료의 개선 가능성을 높일 수 있습니다. 온콜로바이러스 치료에 대한 의료 전문가, 환자 및 일반 대중의 인식과 교육이 높아지면서 온콜로바이러스 치료의 수용과 채택에 기여하고 있습니다.
주요 시장 성장 촉진요인
조사의 진전
주요 시장 이슈
효과와 안전에 대한 우려
주요 시장 동향
다양한 바이러스 플랫폼
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 종양용해성 바이러스 요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 바이러스 유형별(아데노바이러스, 단순 헤르페스 바이러스(HSV), 홍역 바이러스, 레오 바이러스, 백시니아 바이러스, 수포성 구내염 바이러스(VSV), 기타)
- 용도별(고형 종양, 조혈 악성 종양)
- 최종사용자별(병원, 암 연구기관, 바이오의약품 기업)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 종양용해성 바이러스 요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 종양용해성 바이러스 요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 국가별
- 유럽 : 국가별 분석
제8장 북미의 종양용해성 바이러스 요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 국가별
- 북미 : 국가별 분석
제9장 남미의 종양용해성 바이러스 요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 종양용해성 바이러스 요법 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 종양용해성 바이러스 요법 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Amgen Inc.
- Merck & Co., Inc.
- Oncolytics Biotech Inc
- PsiOxus Therapeutics Ltd.
- Vyriad, Inc.
- Cold Genesys Inc.
- Sorrento Therapeutics, Inc.
- Takara Bio Inc.
- Replimune Group Inc.
- Genelux Corporation
제17장 전략적 제안
제18장 리서치사에 대해 & 면책사항
LSH
Global Oncolytic Virus Therapy Market was valued at USD 16.57 billion in 2024 and is expected to reach USD 57.15 billion by 2030 with a CAGR of 22.92% during the forecast period. Oncolytic viruses are a class of viruses that can infect and selectively replicate in cancer cells, leading to their destruction or causing them to undergo programmed cell death (apoptosis). These viruses are engineered or naturally occurring to exhibit a tumor-selective preference, meaning they have an innate ability to target and replicate within cancerous cells while sparing normal, healthy cells. Oncolytic viruses have gained attention and significance in the field of cancer therapy due to their potential as a targeted and innovative treatment approach. Oncolytic viruses have an inherent preference for infecting and replicating within cancer cells. This selectivity is often based on differences in cellular factors and molecular characteristics between cancer cells and healthy cells. Once inside cancer cells, oncolytic viruses replicate and multiply. This replication eventually leads to the lysis (bursting) of the cancer cell, releasing newly formed viral particles that can infect adjacent cancer cells. This process continues, effectively spreading the infection throughout the tumor.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 16.57 Billion |
| Market Size 2030 | USD 57.15 Billion |
| CAGR 2025-2030 | 22.92% |
| Fastest Growing Segment | Herpes Simplex Virus (HSV) |
| Largest Market | North America |
Ongoing research has deepened our understanding of oncolytic viruses, leading to the development of more potent and targeted therapies. This scientific progress drives innovation in the field. Positive outcomes in clinical trials and real-world applications of oncolytic virus therapies for various cancer types have boosted confidence in their efficacy. Demonstrating survival benefits and improved outcomes for patients has been a key driver. The concept of combining oncolytic virus therapy with other treatment modalities, such as immunotherapies or targeted therapies, has gained traction. This combination approach enhances the potential for better cancer treatment outcomes. Increased awareness and education about oncolytic virus therapy among healthcare professionals, patients, and the public have contributed to its acceptance and adoption.
Key Market Drivers
Advancements in Research
Researchers have made significant progress in genetically engineering oncolytic viruses to enhance their tumor-selectivity and therapeutic effectiveness. This includes modifying the virus's ability to replicate in cancer cells while sparing healthy cells. Combining oncolytic virus therapy with other cancer treatments, such as immunotherapies (e.g., immune checkpoint inhibitors) and targeted therapies, has shown promise in improving overall treatment outcomes. Researchers are exploring the best combinations and treatment sequences. Research efforts have led to the development of safer oncolytic viruses with reduced potential for off-target effects. Safety is a critical consideration in regulatory approval and clinical use. The human immune system can neutralize oncolytic viruses. Researchers are developing strategies to evade the host immune response or to enhance the immunostimulatory effects of oncolytic viruses, making them more effective in combating cancer.
Identifying biomarkers that can predict a patient's response to oncolytic virus therapy is a key area of research. This enables a more personalized approach to treatment and ensures that therapy is administered to those who are most likely to benefit. Research has led to innovations in the delivery of oncolytic viruses to tumor sites. This includes the use of nanoparticles, viral vectors, and specialized delivery vehicles to enhance the efficiency of virus delivery. While the Herpes Simplex Virus (HSV) has been prominent, research has expanded to include other virus platforms, such as adenoviruses, reoviruses, and poxviruses. Exploring a variety of virus platforms broadens the scope of oncolytic virus therapy. Ongoing clinical trials have explored the use of oncolytic virus therapy in various cancer types and at different stages of disease. These trials provide valuable data on safety and efficacy, helping to refine treatment protocols.
Key Market Challenges
Efficacy and Safety Concerns
Efficacy can vary among different patients and cancer types. Not all patients respond equally to oncolytic virus therapy, and identifying predictors of response is an ongoing challenge. Tumors are biologically diverse, and this heterogeneity can affect the ability of oncolytic viruses to target and destroy cancer cells effectively. Adapting therapies to address tumor heterogeneity remains a challenge. The tumor microenvironment can be immunosuppressive, hindering the immune system's response to oncolytic viruses. Strategies to overcome immunosuppression are under investigation. Ensuring that oncolytic viruses specifically target cancer cells while sparing healthy tissue is a safety concern. Reducing off-target effects and minimizing collateral damage is a research priority. Tumors can develop resistance to oncolytic virus therapy over time, limiting its long-term effectiveness. Understanding and mitigating resistance mechanisms is a complex challenge. Safety concerns arise from the potential for oncolytic viruses to cause adverse events. Balancing the need for a potent antitumor effect with acceptable safety profiles is a delicate balance.
Key Market Trends
Diverse Virus Platforms
Different virus platforms have unique mechanisms of tumor selectivity, replication kinetics, and host interactions. Researchers are studying these properties to optimize each platform for specific cancer types and patient populations. Combining different virus platforms with one another or with other cancer treatments, such as immunotherapies or targeted therapies, is a growing trend. These combinations offer the potential for enhanced therapeutic effects and expanded applications. The diversity of virus platforms allows for a more personalized approach to treatment. By selecting the most suitable virus platform based on a patient's cancer characteristics, oncolytic virus therapy can be tailored to individual needs. The use of diverse virus platforms can help overcome challenges related to resistance mechanisms that tumors may develop against a particular virus. By switching to a different virus platform, clinicians can potentially re-sensitize the tumor to therapy. Different virus platforms come with varying safety profiles. Researchers aim to identify platforms that minimize off-target effects and adverse events while maximizing antitumor effects. The choice of virus platform can influence the method of delivery, such as intratumoral injection, intravenous administration, or targeted delivery systems. These strategies are designed to enhance virus distribution and tumor penetration.
Key Market Players
- Amgen Inc.
- Merck & Co., Inc.
- Oncolytics Biotech Inc.
- PsiOxus Therapeutics Ltd.
- Vyriad, Inc.
- SillaJen Biotherapeutics
- Cold Genesys Inc.
- Sorrento Therapeutics, Inc.
- Takara Bio Inc.
- Replimune Group Inc.
- Genelux Corporation
Report Scope:
In this report, the Global Oncolytic Virus Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Oncolytic Virus Therapy Market, By Virus Type:
- Adenovirus
- Herpes Simplex Virus (HSV)
- Measles Virus
- Reovirus
- Vaccinia Virus
- Vesicular Stomatitis Virus (VSV)
- Others
Oncolytic Virus Therapy Market, By Application:
- Solid Tumors
- Hematological Malignancies
Oncolytic Virus Therapy Market, By End-User:
- Hospitals
- Cancer Research Institutes
- Biopharmaceutical Companies
Oncolytic Virus Therapy Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Oncolytic Virus Therapy Market.
Available Customizations:
Global Oncolytic Virus Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Applications
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncolytic Virus Therapy Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others)
- 5.2.2. By Application (Solid Tumors, Hematological Malignancies)
- 5.2.3. By End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Oncolytic Virus Therapy Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Virus Type
- 6.2.2. By Application
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Oncolytic Virus Therapy Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Virus Type
- 6.3.1.2.2. By Application
- 6.3.1.2.3. By End User
- 6.3.2. India Oncolytic Virus Therapy Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Virus Type
- 6.3.2.2.2. By Application
- 6.3.2.2.3. By End User
- 6.3.3. Australia Oncolytic Virus Therapy Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Virus Type
- 6.3.3.2.2. By Application
- 6.3.3.2.3. By End User
- 6.3.4. Japan Oncolytic Virus Therapy Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Virus Type
- 6.3.4.2.2. By Application
- 6.3.4.2.3. By End User
- 6.3.5. South Korea Oncolytic Virus Therapy Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Virus Type
- 6.3.5.2.2. By Application
- 6.3.5.2.3. By End User
7. Europe Oncolytic Virus Therapy Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Virus Type
- 7.2.2. By Application
- 7.2.3. By End User
- 7.2.4 By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Oncolytic Virus Therapy Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Virus Type
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By End User
- 7.3.2. Germany Oncolytic Virus Therapy Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Virus Type
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By End User
- 7.3.3. Spain Oncolytic Virus Therapy Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Virus Type
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By End User
- 7.3.4. Italy Oncolytic Virus Therapy Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Virus Type
- 7.3.4.2.2. By Application
- 7.3.4.2.3. By End User
- 7.3.5. United Kingdom Oncolytic Virus Therapy Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Virus Type
- 7.3.5.2.2. By Application
- 7.3.5.2.3. By End User
8. North America Oncolytic Virus Therapy Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Virus Type
- 8.2.2. By Application
- 8.2.3. By End User
- 8.2.4 By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Oncolytic Virus Therapy Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Virus Type
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By End User
- 8.3.2. Mexico Oncolytic Virus Therapy Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Virus Type
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By End User
- 8.3.3. Canada Oncolytic Virus Therapy Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Virus Type
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By End User
9. South America Oncolytic Virus Therapy Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Virus Type
- 9.2.2. By Application
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Oncolytic Virus Therapy Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Virus Type
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Oncolytic Virus Therapy Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Virus Type
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Oncolytic Virus Therapy Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Virus Type
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By End User
10. Middle East and Africa Oncolytic Virus Therapy Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Virus Type
- 10.2.2. By Application
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Oncolytic Virus Therapy Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Virus Type
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Oncolytic Virus Therapy Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Virus Type
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By End User
- 10.3.3. UAE Oncolytic Virus Therapy Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Virus Type
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Oncolytic Virus Therapy Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Amgen Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
- 16.2. Merck & Co., Inc.
- 16.3. Oncolytics Biotech Inc
- 16.4. PsiOxus Therapeutics Ltd.
- 16.5. Vyriad, Inc.
- 16.6. Cold Genesys Inc.
- 16.7. Sorrento Therapeutics, Inc.
- 16.8. Takara Bio Inc.
- 16.9. Replimune Group Inc.
- 16.10. Genelux Corporation
17. Strategic Recommendations
18. About Us & Disclaimer
